Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.
The region of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 that engages its primary cellular receptor CD4 forms a site of vulnerability to neutralizing antibodies. The monoclonal antibody b12 exploits the conservation and accessibility of the CD4-binding site to neutralize many, though not all, HIV-1 isolates. To understand the basis of viral resistance to b12, we used the atomic-level definition of b12-gp120 contact sites to study a panel of diverse circulating viruses. A combination of sequence analysis, computational modeling, and site-directed mutagenesis was used to determine the influence of amino acid variants on binding and neutralization by b12. We found that several substitutions within the dominant b12 contact surface, called the CD4-binding loop, mediated b12 resistance, and that these substitutions resided just proximal to the known CD4 contact surface. Hence, viruses varied in key b12 contact residues that are proximal to, but not part of, the CD4 contact surface. This explained how viral isolates were able to evade b12 neutralization while maintaining functional binding to CD4. In addition, some viruses were resistant to b12 despite minimal sequence variation at b12 contact sites. Such neutralization resistance usually could be reversed by alterations at residues thought to influence the quaternary configuration of the viral envelope spike. To design immunogens that elicit neutralizing antibodies directed to the CD4-binding site, researchers need to address the antigenic variation within this region of gp120 and the restricted access to the CD4-binding site imposed by the native configuration of the trimeric viral envelope spike.
Wu
Xueling
X
Vaccine Research Center, NIAID, NIH, 40 Convent Dr., Bethesda, MD 20892, USA.
Zhou
Tongqing
T
O'Dell
Sijy
S
Wyatt
Richard T
RT
Kwong
Peter D
PD
Mascola
John R
JR
D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D015704:CD4 Antigens / Q000235:genetics / Q000276:immunology*; D000939:Epitopes / Q000737:chemistry / Q000235:genetics; D014644:Genetic Variation; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000235:genetics* / Q000276:immunology*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D008958:Models, Molecular; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D017434:Protein Structure, Tertiary; D016415:Sequence Alignment; D020539:Sequence Analysis, Protein
D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D000939:Epitopes; D015699:HIV Envelope Protein gp120
Science. 1994 Nov 11;266(5187):1024-7
7973652
J Virol. 2003 Jan;77(1):642-58
12477867
J Virol. 2009 Jan;83(2):757-69
18987148
Nature. 1996 Sep 26;383(6598):350-4
8848050
J Virol. 1998 May;72(5):3512-9
9557629
Nature. 2008 Sep 4;455(7209):109-13
18668044
J Virol. 1999 Oct;73(10):8873-9
10482646
J Acquir Immune Defic Syndr (1988). 1992;5(3):303-7
1740756
Annu Rev Immunol. 2006;24:739-69
16551265
J Virol. 1995 Jan;69(1):101-9
7527081
J Virol. 2007 Jun;81(12):6548-62
17409160
Virology. 1991 Nov;185(1):162-8
1926772
Curr Mol Med. 2003 May;3(3):209-16
12699358
J Virol. 1997 Sep;71(9):6869-74
9261412
J Virol. 2006 Dec;80(23):11776-90
16971434
Virology. 1991 Jun;182(2):635-43
1708933
J Virol. 2009 Apr;83(8):3798-809
19193800
J Virol. 2008 Jan;82(2):638-51
17959660
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9
12644702
J Virol. 2004 Jun;78(11):5651-7
15140962
J Virol. 2001 May;75(9):4208-18
11287570
Science. 2004 Mar 26;303(5666):2019-22
15044802
Curr Pharm Des. 2007;13(2):213-27
17269929
Virology. 2007 Oct 10;367(1):222-34
17599380
Nat Med. 2007 Sep;13(9):1032-4
17721546
Immunity. 1999 Apr;10(4):431-8
10229186
J Virol. 2002 Oct;76(19):9888-99
12208966
J Virol. 2005 May;79(10):6523-7
15858036
Acta Crystallogr D Biol Crystallogr. 2001 Jan;57(Pt 1):168-71
11134947
Nature. 1998 Jun 18;393(6686):705-11
9641684
J Virol. 2004 Dec;78(23):13232-52
15542675
Expert Rev Vaccines. 2006 Aug;5(4):579-95
16989638
J Acquir Immune Defic Syndr (1988). 1994 Mar;7(3):211-9
8106963
J Virol. 2003 Jun;77(12):6965-78
12768015
Retrovirology. 2008 Jan 31;5:10
18237398
BMC Bioinformatics. 2007 Nov 22;8:460
18034891
J Infect Dis. 1994 Nov;170(5):1141-7
7963706
J Virol. 2008 Jun;82(12):5807-14
18385254
J Virol. 2009 Jan;83(2):1045-59
19004942
Nature. 2007 Feb 15;445(7129):732-7
17301785
PLoS Pathog. 2007 Aug 24;3(8):e117
17722977
J Virol. 1997 May;71(5):3734-41
9094648
Vaccine. 2007 Feb 9;25(8):1398-408
17113201
Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9339-43
1384050
PLoS Med. 2008 Jan 3;5(1):e9
18177204
J Infect Dis. 1990 Sep;162(3):735-7
2387997
Nature. 2003 Mar 20;422(6929):307-12
12646921
J Biol Chem. 1989 Sep 5;264(25):14587-90
2670920
Virology. 2003 Sep 1;313(2):387-400
12954207
AIDS Res Hum Retroviruses. 2006 May;22(5):430-7
16706620
J Mol Graph. 1993 Jun;11(2):139-41
8347567
J Virol. 1994 Aug;68(8):4821-8
7518527
J Virol. 2005 Aug;79(16):10108-25
16051804
J Virol. 2006 Jan;80(2):835-44
16378985
J Virol. 2001 Apr;75(7):3435-43
11238869
J Virol. 1998 Dec;72(12):10270-4
9811774
Br Med Bull. 2001;58:19-42
11714622
J Virol. 2006 Oct;80(19):9586-98
16973562
J Virol. 2008 Dec;82(23):11651-68
18815292
J Virol. 2003 Jan;77(2):1084-91
12502824